The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: A case-control study

Anaerobe

Volumn 27, Issue , 2014, Pages 82-86

  Islam, J ^a   Taylor, A L ^a   Rao, K ^c   Huffnagle, G ^c   Young, V B ^c   Rajkumar, C ^b   Cohen, J ^a   Papatheodorou, P ^d   Aronoff, D M ^c   Llewelyn, M J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Case control study; Clostridium difficile; Humoral immune response; Toxin A (TcdA); Toxin B (TcdB)

Indexed keywords

BACTERIUM ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN A ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXIN B ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; UNCLASSIFIED DRUG; ACTIN-SPECIFIC ADP-RIBOSYLTRANSFERASE, CLOSTRIDIUM; ANTITOXIN; BACTERIAL PROTEIN; IMMUNOGLOBULIN A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL PATIENT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; MALE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; CASE CONTROL STUDY; CLOSTRIDIUM INFECTIONS; DISEASE PREDISPOSITION; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADP RIBOSE TRANSFERASES; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL PROTEINS; CASE-CONTROL STUDIES; CLOSTRIDIUM INFECTIONS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; MALE; MIDDLE AGED;

EID: 84899054772     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.03.011     Document Type: Article

References (29)

1. Freeman J., Bauer M.P., Baines S.D., Corver J., Fawley W.N., Goorhuis B., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010 Jul 1, 23(3):529-549.
2. Riggs M.M., Sethi A.K., Zabarsky T.F., Eckstein E.C., Jump R.L., Donskey C.J. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45(8):992-998.
3. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. NEngl J Med 2002, 346(5):334-339.
4. Eyre D.W., Walker A.S., Griffiths D., Wilcox M.H., Wyllie D.H., Dingle K.E., et al. Clostridium difficile mixed infection and reinfection. JClin Microbiol 2012 Jan, 50(1):142-144.
5. Eyre D.W., Walker A.S., Wyllie D., Dingle K.E., Griffiths D., Finney J., et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis Off Publ Infect Dis Soc Am 2012 Aug, 55(Suppl.2):S77-S87.
6. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. NEngl J Med 2000 Feb 10, 342(6):390-397.
7. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001 Jan 20, 357(9251):189-193.
8. Lyras D., O'Connor J.R., Howarth P.M., Sambol S.P., Carter G.P., Phumoonna T., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009 Apr 30, 458(7242):1176-1179.
9. Kuehne S.A., Cartman S.T., Heap J.T., Kelly M.L., Cockayne A., Minton N.P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010 Oct 7, 467(7316):711-713.
10. Health Protection Agency B 10-Processing of faeces for Clostridium difficile. http://www.hpa.org.uk/ProductsServices/MicrobiologyPathology/UKStandardsForMicrobiologyInvestigations.
11. Yang G., Zhou B., Wang J., He X., Sun X., Nie W., et al. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 2008 Nov 6, 8:192.
12. Guttenberg G., Papatheodorou P., Genisyuerek S., Lü W., Jank T., Einsle O., et al. Inositol hexakisphosphate-dependent processing of Clostridium sordellii lethal toxin and Clostridium novyi alpha-toxin. JBiol Chem 2011 Apr 29, 286(17):14779-14786.
13. Bacon A.E., Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis 1994 Apr, 18(4):205-209.
14. Viscidi R., Laughon B.E., Yolken R., Bo-Linn P., Moench T., Ryder R.W., et al. Serum antibody response to toxins A and B of Clostridium difficile. JInfect Dis 1983 Jul, 148(1):93-100.
15. Lyerly D.M., Saum K.E., MacDonald D.K., Wilkins T.D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985 Feb, 47(2):349-352.
16. Solomon K., Martin A.J., O'Donoghue C., Chen X., Fenelon L., Fanning S., et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. JMed Microbiol 2013 Sep, 62(Pt 9):1453-1460.
17. Leav B.A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010 Jan 22, 28(4):965-969.
18. Drudy D., Calabi E., Kyne L., Sougioultzis S., Kelly E., Fairweather N., et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 2004 Jul 1, 41(3):237-242.
19. Drudy D., Fanning S., Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 2007 Jan, 11(1):5-10.
20. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. NEngl J Med 1989, 320(4):204-210.
21. Elixhauser A., L J. Clostridium difficile infections (CDI) in hospital stays 2009, 2012 Jan. Available from:. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf.
22. Health protection agency & Department of Health Clostridium difficile infection: how to deal with the problem 2009, http://www.dh.gov.uk/en.
23. Franceschi C., Bonafè M., Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 2000 Feb 25, 18(16):1717-1720.
24. Externest D., Meckelein B., Schmidt M.A., Frey A. Correlations between antibody immune responses at different mucosal effector sites are controlled by antigen type and dosage. Infect Immun 2000 Jul, 68(7):3830-3839.
25. Johnson S., Gerding D.N., Janoff E.N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. JInfect Dis 1992 Dec, 166(6):1287-1294.
26. Wilson V., Cheek L., Satta G., Walker-Bone K., Cubbon M., Citron D., et al. Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis Off Publ Infect Dis Soc Am 2010 Jun 15, 50(12):e77-e81.
27. Walk S.T., Micic D., Jain R., Lo E.S., Trivedi I., Liu E.W., et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis Off Publ Infect Dis Soc Am 2012 Dec, 55(12):1661-1668.
28. Lanis J.M., Barua S., Ballard J.D. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 2010, 6(8):e1001061.
29. Lanis J.M., Heinlen L.D., James J.A., Ballard J.D. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 2013 Aug 1, 9(8):e1003523.